Capture NIH Gene Therapy Portfolio via Bridge SPV & Regulatory Navigation
- Organization
- NIH/National Eye Institute STTR Phase I funding mechanism
- Sector
- Large pharmaceutical companies seeking early-stage gene therapy assets
- Location
- Portland, OR (OUTFLOWGEN LLC)
Source Reference
Executive Context
NIH awarded $311,049 Phase I STTR funding to OUTFLOWGEN LLC for a first-in-class CRISPR glaucoma therapy, creating a predictable commercial gap where scientific validation exists but commercialization infrastructure is absent. The structural asymmetry is between NIH's ability to fund early science and small biotechs' inability to navigate the regulatory and capital requirements for clinical development.
Catalyst / Timing
NIH's STTR Phase I grants provide scientific validation but create a predictable 'valley of death' between Phase I completion ($311k) and Phase II/IND readiness ($50-100M+). Small biotechs like OUTFLOWGEN LLC have deep technical expertise but zero commercialization infrastructure, regulatory navigation capability, or late-stage capital access.
Projected Yield
$15-25M portfolio exit on $1-2M deployed capital (10-15x return)
Structural Friction
• Vulnerability: NIH's STTR Phase I grants provide scientific validation but create a predictable 'valley of death' between Phase I completion ($311k) and Phase II/IND readiness ($50-100M+). Small biotechs like OUTFLOWGEN LLC have deep technical expertise but zero commercialization infrastructure, regulatory navigation capability, or late-stage capital access. • Capital yield: $15-25M portfolio exit on $1-2M deployed capital (10-15x return) • Resource capture: Exclusive access to NIH-validated gene therapy pipeline before traditional VCs discover them • Influence capture: First-mover position as specialized bridge financier for NIH STTR gap • Sovereignty yield: Control over 5-8 early-stage gene therapy assets via convertible debt positions • Required vectors: Vector: Biotech Finance & SPV Structuring, Vector: Regulatory Affairs (FDA/IND), Vector: IP Due Diligence, Vector: Pharma Business Development
Required Capabilities
Vector: Biotech Finance & SPV Structuring
Primary executor: Phase 1: Portfolio Intelligence & Target Identification: Scrape NIH RePORTER database for all R41/R42 (STTR Phase I/II)
Vector: Regulatory Affairs (FDA/IND)
Supporting vector for: Capture NIH Gene Therapy Portfolio via Bridge SPV & Regulatory Navigation
Vector: IP Due Diligence
Supporting vector for: Capture NIH Gene Therapy Portfolio via Bridge SPV & Regulatory Navigation
Vector: Pharma Business Development
Supporting vector for: Capture NIH Gene Therapy Portfolio via Bridge SPV & Regulatory Navigation
Execution Protocol
Execution Protocol Locked
A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.